Despite its early promise, rational drug design for anti-HIV agents has fallen short of expectations, probably because the expectations were too high.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Abdel-Meguid, S.S. Inhibitors of aspartyl proteinases. Med. Res. Rev. 13, 731–778 (1993).
Pauwels, R. et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343, 470–474 (1990).
Kohlstaedt, L.A., Wang, J., Friedman, J.M., Rice, P.A. & Steitz, T.A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256, 1783–1790 (1992).
Jacobo-Molina, A. et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc. natn. Acad. Sci. U.S.A. 90, 6320–6324 (1993).
Smerdon, S.J. et al. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. natn. Acad. Sci. U.S.A. 91, 3911–3915 (1994).
Ding, J. et al. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 Å resolution. Structure 3 365–379 (1995).
Ren, J.S. et al. High resolution structure of HIV-1 RT: Insights from four RT-inhibitor complexes. Nature struct. Biol. 2 293–302 (1995).
Esnouf, R. et al. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nature struct. Biol. 2 303–308 (1995).
Rodgers, D.W. et al. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc. natn. Acad. Sci. U.S.A. 92 1222–1226 (1995).
Spence, R.A., Kati, W.M., Anderson, K.S. & Johnson, K.A. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267 988–993 (1995).
Rittinger, K., Divita, G., Muller, B. & Goody, R.S. HIV reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by non-nucleoside inhibitors. Proc. natn. Acad. Sci. U.S.A. (in the press).
Collins, J.R., Burt, S.K. & Erickson, J.W. Flap opening in HIV-1 protease simulated by ‘activated’ molecular dynamics. Nature struct. Biol. 2 334–338 (1995).
Caspar, D. Problems in simulating macromolecular movements. Structure 3 327–329 (1995).
Condra, J.H. et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569–571 (1995).
Tisdale, M., Kemp, S.D., Parry, N.R. & Larder, B.A. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. natn. Acad. Sci. U.S.A. 90, 5653–5656 (1993).
Divita, G., Restle, T., Goody, R.S., Chermann, J.-C. & Baillon, J.G. Inhibition of human immunodeficiency virus type I reverse transcriptase dimerization using synthetic peptides derived from the connection domain. J. biol. Chem. 269, 13080–13083 (1994).
Liuzzi, M. et al. A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo. Nature 372, 695–698 (1994).
Bushman, F. Targeting retroviral integration. Science 267 1443–1444 (1995)
Lasic, D.D. & Papahadjopulos, D. Liposomes revisited. Science 267 1275–1276 (1995).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Goody, R. Rational drug design and HIV: Hopes and limitations. Nat Med 1, 519–520 (1995). https://doi.org/10.1038/nm0695-519
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0695-519
